Anabolic treatments for osteoporosis in postmenopausal women

Neelam Hassan*, Celia L Gregson, Jonathan H Tobias

*Corresponding author for this work

Research output: Contribution to journalReview article (Academic Journal)peer-review


Antiresorptive agents are generally recommended as first-line treatment for osteoporosis in postmenopausal women. These drugs suppress bone resorption but do not rebuild bone, limiting their efficacy. Antiresorptive use is further hampered by concerns over rare side effects, including atypical femoral fractures and osteonecrosis of the jaw. Anabolic treatments overcome limitations of antiresorptive treatment by stimulating new bone formation, reducing the risk of fracture with greater efficacy. This review summarises the latest trial data for the three anabolic agents currently available for the treatment of osteoporosis in postmenopausal women: teriparatide, abaloparatide, and romosozumab. Data from head-to-head studies comparing anabolic and antiresorptive treatments are reviewed. At present, anabolic treatments are generally reserved for use in patients with severe osteoporosis at very high fracture risk; the factors limiting their more widespread use are discussed together with how this may change in the future.
Original languageEnglish
JournalFaculty Opinions
Issue number44
Publication statusPublished - 6 May 2021


Dive into the research topics of 'Anabolic treatments for osteoporosis in postmenopausal women'. Together they form a unique fingerprint.

Cite this